– Gilead Sciences said a late-stage trial of its experimental hepatitis
C treatment showed that the virus was not detected in 78 percent of
patients taking the drug, 12 weeks after completing therapy.
The trial, named Positron, was
testing the drug, sofosbuvir, in patients who were unable or unwilling
to take interferon — a standard hepatitis C drug known for its
unpleasant side effects.
No patient in the placebo group achieved an undetectable virus level 12 weeks after completing the therapy, Gilead said.